Primer on Medical Genomics Part XIV: Introduction to Systems Biology - A New Approach to Understanding Disease and Treatment

Mayo Clinic Proceedings

Volumn 79, Issue 5, 2004, Pages 651-658

  Morel, Nicole M ^a   Holland, Joanne M ^a   Van Der Greef, Jan ^b   Marple, Edward W ^a   Clish, Clary ^a   Loscalzo, Joseph ^c   Naylor, Stephen ^c,d  

^a Waltham MA 02451 USA   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

BIOINFORMATICS; DNA DETERMINATION; GENOMICS; HUMAN; INFORMATION PROCESSING; MASS SPECTROMETRY; MOLECULAR MODEL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 2342630549     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.5.651     Document Type: Article

References (26)

1. Hood L. A personal view of molecular technology and how it has changed biology. J Proteome Res. 2002;1:399-409.
2. Roberts L, Davenport RJ, Pennisi E, Marshall E. A history of the Human Genome Project. Science. 2001;291:1195.
3. Lander ES, Linton LM, Birren B, et al, International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
4. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome [published correction appears in Science. 2001;292:1838]. Science. 2001;291:1304-1351.
5. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome [published correction appears in Science. 2001;292:1838]. Science. 2001;291:1304-1351.
6. Haberman A. Potential of systems biology and pathways studies. Genet Eng News. 2002;22:26-32.
7. Abbott A. And now for the proteome. Nature. 2001;409:747.
8. van der Greef J, Davidov E, Verheij E, et al. The role of metabolomics in systems biology. In: Harrigan GG, Goodacre R, eds. Metabolite Profiling: Its Role in Biomarker Discovery and Gene Function Analysis. Boston, Mass: Kluwer Academic Publishers; 2003:171-198.
9. Cockett M, Dracopoli N, Sigal E. Applied genomics: integration of the technology within pharmaceutical research and development. Curr Opin Biotechnol. 2000;11:602-609.
10. Ideker T, Thorsson V, Ranish JA, et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science. 2001;292:929-934.
11. Kitano H. Foundations of Systems Biology. Cambridge, Mass: MIT Press; 2001.
12. Kitano H. Systems biology: a brief overview. Science. 2002;295:1662-1664.
13. Hood L. Systems biology: integrating technology, biology, and computation. Mech Ageing Dev. 2003;124:9-16.
14. Davidov E, Holland J, Marple E, Naylor S. Advancing drug discovery through systems biology. Drug Discov Today. 2003;8:175-183.
15. Neumann E, Thomas J. Knowledge assembly for the life sciences. Drug Discov Today. 2002;7(20, suppl):S160-S162.
16. Kitano H. Computational systems biology. Nature. 2002;420:206-210.
17. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 2001;104:517-529.
18. Chakrabarti R, Rajagopalan R. Diabetes and insulin resistance associated disorders: disease and the therapy. Curr Sci. 2002;83:1533-1538.
19. Clish CB, Davidov E, Oresic M, et al. Integrative biological analysis of the APOE*3-Leiden transgenic mouse. OMICS. 2004;8:3-13.
20. Lutgens E, Daemen M, Kockx M, et al. Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage. Circulation. 1999;99:276-283.
21. Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci U S A. 2000;97:12182-12186.
22. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci. 2001;22:368-376.
23. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1:727-730.
24. Terret NK, Bell AS, Brown D, Ellis P. Sildenafil (VIAGRA™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett. 1996;6:1819-1824.
25. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493-502.
26. Naylor S. Biomarkers: current perspectives and future prospects [editorial]. Expert Rev Mol Diagn. 2003;3:525-529.